Dianthus Therapeutics (NASDAQ:DNTH) Given “Buy” Rating at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $158.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 112.22% from the company’s current price.

A number of other research analysts have also recently commented on DNTH. JPMorgan Chase & Co. initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 target price for the company. Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Citigroup started coverage on shares of Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 price objective for the company. Finally, Wedbush raised their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $129.83.

Dianthus Therapeutics Trading Down 0.4%

Dianthus Therapeutics stock traded down $0.31 on Thursday, reaching $74.45. 943,572 shares of the stock were exchanged, compared to its average volume of 930,367. The firm has a fifty day moving average price of $100.75 and a two-hundred day moving average price of $94.49. Dianthus Therapeutics has a twelve month low of $32.22 and a twelve month high of $117.88. The stock has a market cap of $4.08 billion, a PE ratio of -17.94 and a beta of 1.35.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Equities analysts anticipate that Dianthus Therapeutics will post -3.81 EPS for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In other news, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the transaction, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at $7,058,718.12. This trade represents a 71.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Adam Veness sold 16,167 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the completion of the sale, the senior vice president owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. This represents a 80.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 242,429 shares of company stock valued at $26,118,913. 3.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics during the first quarter worth $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $43,000. EFG International AG acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $49,000. GAMMA Investing LLC raised its holdings in shares of Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after acquiring an additional 254 shares during the period. Finally, Global Retirement Partners LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $93,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.